Novapeutics LLC is a biopharmaceutical company spun-out from the University of Pennsylvania that aims to develop a first-in-class, oral curative therapeutic to reverse the course of diabetes by regenerating insulin-producing beta cells. Our approach utilizes small molecule therapeutics to to disrupt menin and mixed lineage leukemia (MLL) proteins, known as a menin inhibitor, which enhancing endogenous beta cell regeneration in diabetes patients. Currently with the support of the SBIR funding from NIH/NIDDK, we have identified promising novel menin inhibitors as our drug leads.